A Brief History of Guardant Health, Inc. (GH)
Founding and Early Years
Founding and Early Years
Guardant Health, Inc. was founded in 2012 by Dr. AmirAli Talasaz and Dr. Helmy Eltoukhy. The company is headquartered in Redwood City, California.
In its initial years, Guardant Health focused on developing non-invasive blood tests for cancer detection and monitoring, utilizing liquid biopsy technology.
Product Development
In 2014, Guardant Health launched its first product, the Guardant360 test, which allows oncologists to obtain genomic information about cancer from a simple blood draw. This test analyzes over 70 genes associated with cancer.
The Guardant360 test gained significant traction in the clinical setting and was used in over 60,000 patients by 2019.
Funding and Growth
Guardant Health has successfully raised substantial funds over the years. In 2018, the company completed an initial public offering (IPO), raising approximately $238 million. This IPO valued the company at around $1.5 billion.
By the end of 2020, Guardant Health had raised a total of around $1.4 billion across various funding rounds.
Recent Financial Performance
For the fiscal year ending December 31, 2022, Guardant Health reported revenues of $305.9 million, a growth of approximately 40% compared to 2021.
The company’s net loss for 2022 was approximately $80.1 million, reflecting its continued investment in R&D and expansion of product offerings.
Partnerships and Collaborations
In 2020, Guardant Health announced a strategic partnership with U.S. Oncology to integrate the Guardant360 test into their cancer treatment protocols.
Additionally, the company has collaborated with major pharmaceutical firms such as Genentech and AstraZeneca for pivotal studies related to targeted therapies.
Market Position and Valuation
As of September 2023, Guardant Health holds a significant share in the liquid biopsy market, valued at approximately $2.5 billion.
The company's stock price, as of September 2023, was about $18.72 per share, with a market capitalization of roughly $1.8 billion.
Global Presence and Impact
Guardant Health's products have been utilized in clinical practices across over 40 countries, demonstrating the global demand for advanced cancer diagnostics.
The company continues to invest heavily in clinical trials, with over 20 ongoing studies focused on various types of cancer therapy response monitoring.
Table: Financial Summary of Guardant Health, Inc.
| Year | Revenue (in million $) | Net Loss (in million $) | IPO Amount (in million $) | Market Share % (2023) |
|---|---|---|---|---|
| 2020 | 217.0 | 38.0 | ||
| 2021 | 218.5 | 70.4 | ||
| 2022 | 305.9 | 80.1 | ||
| 2023 (est.) | 350.0 | 90.0 | 238.0 | 25.0 |
Future Prospects
Looking ahead, Guardant Health is focused on expanding its product offerings and clinical applications of its tests, particularly in early detection of cancer through the Guardant Reveal test.
The company aims to enhance its portfolio by investing an estimated $150 million in R&D between 2023 and 2024.
A Who Owns Guardant Health, Inc. (GH)
Corporate Structure
Guardant Health, Inc. is publicly traded on the NASDAQ under the ticker symbol GH. As of October 2023, the company has been structured such that it allows for diverse ownership, including institutional and retail investors.
Major Shareholders
The ownership of Guardant Health is divided among various categories of investors. Below is a table detailing the major shareholders and their respective ownership percentages as of the latest available data:
| Shareholder | Ownership Percentage | Shares Owned |
|---|---|---|
| Vanguard Group, Inc. | 11.5% | 5,053,000 |
| BlackRock, Inc. | 10.2% | 4,500,000 |
| FMR LLC (Fidelity) | 9.9% | 4,300,000 |
| Sacconaghi Family Trust | 7.8% | 3,450,000 |
| State Street Corporation | 7.1% | 3,100,000 |
Insider Ownership
Insider ownership is an important aspect when evaluating the alignment of interests between management and shareholders. The following table summarizes the insider ownership at Guardant Health:
| Insider Name | Position | Shares Owned |
|---|---|---|
| Helmy Eltoukhy | CEO | 1,250,000 |
| Amirali Talasaz | Co-Founder, President | 900,000 |
| Allison M. C. Kahn | CFO | 400,000 |
| Sanjay A. S. Bhatia | VP of Operations | 200,000 |
Institutional Ownership Trends
Institutional investors play a significant role in the stock market. Below is a summary of the institutional ownership trends for Guardant Health:
| Year | Percentage Owned by Institutions | Total Institutional Shares |
|---|---|---|
| 2023 | 73.5% | 32,000,000 |
| 2022 | 70.2% | 29,000,000 |
| 2021 | 68.0% | 26,000,000 |
Stock Performance
The stock performance of Guardant Health is crucial for understanding market sentiment:
| Date | Closing Price (USD) | Market Capitalization (USD) |
|---|---|---|
| October 1, 2023 | 30.50 | 3.14 billion |
| September 1, 2023 | 28.00 | 2.95 billion |
| August 1, 2023 | 27.50 | 2.85 billion |
Conclusion
Guardant Health, Inc. has a diverse ownership structure that consists of both institutional and insider shareholders, reflecting its position in the biotechnology sector and its market valuation.
Guardant Health, Inc. (GH) Mission Statement
Company Overview
Guardant Health, Inc. operates in the biotechnology sector, specifically focusing on the development of non-invasive blood tests for cancer detection and monitoring. The company is primarily known for its flagship product, Guardant360, which utilizes advanced genomic sequencing technology.
Mission Statement
The mission of Guardant Health is to “transform cancer care through data-driven insights.” The company aims to provide oncologists with vital information that can guide treatment decisions and improve patient outcomes.
Key Objectives
- Innovate and enhance genomic testing technologies.
- Increase accessibility to liquid biopsy tests.
- Improve patient outcomes through actionable insights derived from genomic data.
Financial Highlights
As of the latest fiscal reports for Q3 2023, Guardant Health reported the following financial statistics:
| Metric | Q3 2023 Amount | Year-over-Year Change |
|---|---|---|
| Revenue | $105 million | +13% |
| Net Loss | - $35 million | -1% from Q3 2022 |
| Cash and Cash Equivalents | $600 million | N/A |
| Total Assets | $1.1 billion | +10% |
Product Offerings
Guardant Health’s product suite includes:
- Guardant360
- GuardantOMNI
- Guardant Reveal
Market Position
As of October 2023, Guardant Health is a leading player in the liquid biopsy market. The global liquid biopsy market size was valued at approximately $3.3 billion in 2022 and is expected to reach $7.8 billion by 2029 according to market research.
Recent Achievements
In Q3 2023, Guardant Health received the following recognitions and milestones:
- FDA approval for a new liquid biopsy test.
- Partnership with major oncology centers for clinical trials.
- Published in peer-reviewed journals highlighting the accuracy of their tests.
Strategic Initiatives
The company has outlined several strategic initiatives to further its mission:
- Expand R&D for new cancer biomarkers.
- Enhance patient education on the benefits of liquid biopsies.
- Increase collaborations with pharmaceutical companies for drug development.
Future Outlook
According to financial analysts, Guardant Health is expected to see a CAGR of approximately 15% through 2025 due to the growing demand for personalized cancer treatment options and non-invasive testing methods.
Corporate Responsibility
Guardant Health is committed to improving healthcare access and is involved in various community initiatives aimed at cancer education and support.
How Guardant Health, Inc. (GH) Works
Company Overview
Guardant Health, Inc. (GH) is a biotechnology company that specializes in non-invasive cancer genomic testing. The company focuses on liquid biopsies, utilizing blood samples to identify genetic mutations associated with cancer.
Business Model
Guardant Health operates primarily through its flagship product, the Guardant360, which provides comprehensive genomic profiling for patients with advanced cancer. The company's revenues are generated from:
- Direct sales of genomic tests to oncologists and healthcare institutions.
- Partnerships with pharmaceutical companies for clinical trials.
- Research collaborations and co-development agreements.
Financial Performance
As of the third quarter of 2023, Guardant Health reported:
| Financial Metric | Value (in millions) |
|---|---|
| Revenue | $124.5 |
| Net Income | -$53.6 |
| Gross Profit | $82.1 |
| Operating Expenses | $134.6 |
| Cash and Cash Equivalents | $249.8 |
Market Position
Guardant Health is a leader in the liquid biopsy market. According to a report by Grand View Research, the global liquid biopsy market size was valued at approximately $4.7 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.9% from 2024 to 2030.
Products and Services
Guardant Health's primary offerings include:
- Guardant360: A liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a blood sample.
- Guardant Reveal: A test designed to detect minimal residual disease (MRD) in cancer patients post-treatment.
- GuardantOMNI: A comprehensive genomic profile that includes multiple cancer types.
Partnerships and Collaborations
As of 2023, Guardant Health has entered into several key partnerships:
- Collaboration with AstraZeneca for biomarker discovery.
- Partnership with Merck for clinical trial support.
- Agreements with various research institutions to advance genomic profiling technologies.
Clinical Evidence and Studies
Guardant Health continually invests in clinical studies to validate its tests. Notable studies include:
- The TRACERx study, which evaluated the utility of liquid biopsies in lung cancer.
- Research published in The Journal of Clinical Oncology demonstrating the accuracy of Guardant360 in identifying actionable mutations.
Recent Developments
In 2023, Guardant Health announced:
- The launch of an expanded test menu to include more comprehensive genomic insights.
- Positive results from its clinical trials that support the use of its tests in early cancer detection.
- Increased accessibility through partnerships with healthcare payers for reimbursement of tests.
Future Growth Prospects
Guardant Health's strategic focus areas include:
- Enhancing liquid biopsy technologies for broader applications in oncology.
- Expanding global market reach and establishing new international partnerships.
- Investing in R&D for next-generation sequencing and artificial intelligence in genomics.
Conclusion
Guardant Health, Inc. continues to evolve in the cancer diagnostics market through innovation, strategic partnerships, and a commitment to advancing genomics.
How Guardant Health, Inc. (GH) Makes Money
Revenue Streams
Guardant Health operates primarily through two business segments: Oncology and Guardant Health Diagnostics. The company earns revenue mainly from its advanced genomic tests and related services.
Product Offerings
- Guardant360: A liquid biopsy test that analyzes circulating tumor DNA (ctDNA). As of 2023, this test is priced at approximately $3,500.
- GuardantOMNI: A pan-cancer assay that allows for tumor profiling across multiple types. The price is around $5,000 per test.
- Guardant Insight: A service providing real-time genomic data for treatment decisions, with a cost near $2,000.
Recent Financial Performance
For the full year of 2022, Guardant Health reported a total revenue of $338 million, showing a growth of approximately 25% year-over-year.
The revenue breakdown is as follows:
| Revenue Source | 2022 Revenue (in millions) | Percentage of Total Revenue |
|---|---|---|
| Guardant360 | $210 | 62% |
| GuardantOMNI | $75 | 22% |
| Guardant Insight | $35 | 10% |
| Other Services | $18 | 6% |
Cost Structure
In 2022, the company reported a total operating expense of $405 million, with costs primarily attributed to:
- Research and Development: $183 million
- Sales and Marketing: $132 million
- General and Administrative: $90 million
Market Position and Expansion
Guardant Health has established a competitive position within the oncology diagnostics market, estimated to be worth $47 billion by 2027. The company is focusing on expanding its product offerings and entering global markets.
In 2023, Guardant Health reported partnerships with over 1,000 healthcare providers and institutions, enhancing its market penetration.
Future Projections
Analysts forecast that Guardant Health's revenue will grow at a compound annual growth rate (CAGR) of approximately 20% between 2023 and 2027, projecting total revenues of around $700 million by 2027.
Key Metrics
As of the second quarter of 2023, Guardant Health reported:
| Metric | Value |
|---|---|
| Cash and Cash Equivalents | $350 million |
| Debt | $150 million |
| Gross Margin | ~70% |
| Net Loss | $67 million |
Guardant Health, Inc. (GH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support